Immunologic mechanisms and treatment of acute coronary syndromes

Chinese Medical Journal

Volumn 119, Issue 24, 2006, Pages 2108-2113

  Liu, Ying ^a   Liao, Yu Hua ^a   Cheng, Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute coronary syndrome; Glucocorticosteroids; Immunity; Rapamycin; Stents

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIGEN; ATORVASTATIN; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GATIFLOXACIN; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IRBESARTAN; METHYLPREDNISOLONE; PLACEBO; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIBIOTIC THERAPY; ANTIGEN PRESENTATION; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; LONG TERM CARE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOLECULAR MECHANICS; NONHUMAN; SECONDARY PREVENTION; T LYMPHOCYTE;

EID: 33845877968     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200612020-00014     Document Type: Article

References (38)

1. De Palma R, Del Galdo F, Abbate G, Chiariello M, Calabro R, Forte L, et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 2006; 113: 640-646.
2. +CD28null T cells in patients with acute coronary syndromes. Circulation 2004; 109:1230-1235.
3. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005; 96:427-434.
4. Tobian AA, Harding CV, Canaday DH. Myoobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and -presentation by B lymphocytes. J Immunol 2005; 174: 5209-5214.
5. + T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. Int Immunol 2005; 17: 591-597.
6. Han P, McDonald T, Hodge G. Potential immaturity of the T-cell and antigen-presenting cell interaction in cord blood with particular emphasis on the CD40-CD40 ligand costimulatory pathway. Immunology 2004; 113: 26-34.
7. Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 2006; 176: 5255-5266.
8. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 2005; 45:1939-1945.
9. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113:2245-2252.
10. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003; 338:17-24.
11. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004; 25: 1438-1446.
12. Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K. High-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol 2003; 42: 201-206.
13. Pasqui AL, Di Renzo M, Auteri A, Puccetti L. Cytokines in acute coronary syndromes. Int J Cardiol 2005; 105: 355-356.
14. Alisky JM. Dexamethasone could improve myocardial infarction outcomes and provide new therapeutic options for non-interventional patients. Med Hypotheses 2006; 67: 53-56.
15. Bernauer W. Effects of glucocorticosteroids in rats with acute myocardial infarction. Arch Int Pharmacodyn Ther 1980; 244: 86-99.
16. Ito Y, Matsuura H, Ueba Y, Fukuzaki H. The effects of large doses of dexamethasone on myocardial contractility and calcium metabolism in experimental myocardial infarction. Adv Myocardiol 1980; 2: 457-464.
17. Dudek RR, Wildhirt S, Pinto V, Giesler G, Bing RJ. Dexamethasone inhibits the expression of an inducible nitric oxide synthase in infarcted rabbit myocardium. Biochem Biophys Res Commun 1994; 202: 1120-1126.
18. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8: 473-479.
19. Valen G, Kawakami T, Tahepold P, Dumitrescu A, Lowbeer C, Vaage J. Glucocorticoid pretreatment protects cardiac function and induces cardiac heat shock protein 72. Am J Physiol Heart Circ Physiol 2000; 279: H836-843.
20. Azar RR, Rinfret S, Theroux P, Stone PH, Dakshinamurthy R, Feng YJ, et al. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000; 21: 2026-2032.
21. Mut-Vitcu B, Dragulescu SI, Dragulescu A, EI Kahlout A, Coroban A, Maximov D, et al. Inflammatory response after dexamethasone eluting coronary stent implantation. Rom J Intern Med 2004; 42:119-127.
22. Patti G, Pasceri V, Carminati P, D'Ambrosio A, Carcagni A, Di Sciascio G. Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2005; 95: 502-505.
23. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002; 87: 305-307.
24. Guarda E, Marchant E, Fajuri A, Martinez A, Moran S, Mendez M, et al. Oral rapamycin to prevent human coronary stent restenosis: a pilot study. Am Heart J 2004; 148: e9.
25. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schuhlen H, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790-795.
26. Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, et al. Comparison of effects of drug-eluting stents; versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005; 96:1384-1388.
27. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
28. Chen JL, Gao RL, Yang YJ, Qiao SB, Qin XW, Yao, M, et al. Comparison of short- and mid-term outcomes between CYPHER and TAXUS stents; in patients with complex lesions of the coronary arteries. Chin Med J 2006; 119:21-25.
29. Costa MA, Sabate M, Angiolillo DJ, Jimenez-Quevedo P, Teirstein P, Carter A, et al. Intravascular ultrasound characterization of the "black hole" phenomenon after drug-eluting stent implantation. Am J Cardiol 2006; 97:203-206.
30. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Mad 2000; 6: 1399-1402.
31. Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, Lorz C, Diaz C, Hernandez G, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003; 108: 1506-1513.
32. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004; 175: 83-90.
33. Chang X, Liao YH, Zhang J, Li B, Ge H, Yuan J, et al. Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction. Eur J Heart Fail 2005; 7: 1099-1104.
34. Suliman ME, Qureshi AR, Heimburger O, Lindholm B, Stenvinkel P. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. Nephrol Dial Transplant 2006; 21: 1603-1610.
35. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004; 43: 686-691.
36. Cipollone F, Fazie M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, et al. Blockade of the angiotensin 11 type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2003; 109: 1482-1488.
37. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-1645.
38. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestain B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-1654.